Table of Content

1 Key Insights

2 Report Introduction

3 Chronic Obstructive Pulmonary Disease (COPD) Market Overview at a Glance
3.1 Market Share (%) Distribution of COPD by Class in 2018
3.2 Market Share (%) Distribution of COPD by Class in 2030

4 Executive Summary of Chronic Obstructive Pulmonary Disease (COPD)

5 Key Events

6 Disease Background and Overview
6.1 Introduction
6.2 Factors That Influence Disease Development and Progression
6.3 Symptoms
6.4 Types
6.5 Classification
6.6 Stages
6.7 Pathology, Pathogenesis, and Pathophysiology
6.8 Diagnosis
6.8.1 Differential Diagnosis
6.8.2 Diagnostic Algorithm
6.8.3 Diagnostic Guidelines
6.8.3.1 Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline Update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society
6.8.3.2 Chronic Obstructive Pulmonary Disease: Diagnosis and Management
6.8.3.3 Guidelines for the Diagnosis and Treatment of COPD (Chronic Obstructive Pulmonary Disease) 3rd edition
6.9 Treatment and Management
6.10 Treatment Algorithm Chronic obstructive pulmonary disease (COPD)
6.11 Guidelines
6.11.1 Chronic Obstructive Pulmonary Disease in over 16s: Nonpharmacological Management and Use of Inhaled Therapies: NICE
6.11.2 Chronic Obstructive Pulmonary Disease (COPD) Diagnosis and Treatment Guideline 2020
6.11.3 Global Initiative for Chronic Obstructive Lung Disease Guideline 2021
6.12 Vaccination in COPD
6.12.1 Guidelines for the Diagnosis and Treatment of COPD (Chronic Obstructive Pulmonary Disease) 3rd edition: The Japanese Respiratory Society
6.12.2 Chronic Obstructive Pulmonary Disease (COPD) Diagnosis and Treatment Guideline: Kaiser Foundation Health Plan of Washington

7 Epidemiology and Patient Population
7.1 Key Findings
7.2 Methodology of Epidemiology
7.3 Assumptions and Rationale: 7MM
7.3.1 US Assumptions and Rationale
7.3.2 EU5 Assumptions and Rationale
7.3.3 JP Assumptions and Rationale
7.4 Total Diagnosed Prevalent Patient Population of Chronic Obstructive Pulmonary Disease in the 7MM
7.5 The United States
7.5.1 Diagnosed Prevalent Cases of COPD in the United States
7.5.2 Gender-specific Diagnosed Prevalent Cases of COPD in the United States
7.5.3 Age-specific Diagnosed Prevalent Cases of COPD in the United States
7.5.4 Diagnosed Prevalent Cases of COPD Based on Severity of Airflow Limitation in the United States
7.5.5 Diagnosed Prevalent Cases of COPD Based on Symptoms and Exacerbation History in the United States
7.6 Europe
7.6.1 Diagnosed Prevalent Cases of COPD in Europe
7.6.2 Gender-specific Diagnosed Prevalent Cases of COPD in Europe
7.6.3 Age-specific Diagnosed Prevalent Cases of COPD in Europe
7.6.4 Diagnosed Prevalent Cases of COPD Based on Severity of Airflow Limitation in Europe
7.6.5 Diagnosed Prevalent Cases of COPD Based on Symptoms and Exacerbation History in Europe
7.7 Japan
7.7.1 Diagnosed Prevalent Cases of COPD in Japan
7.7.2 Gender-specific Diagnosed Prevalent Cases of COPD in Japan
7.7.3 Age-specific Diagnosed Prevalent Cases of COPD in Japan
7.7.4 Diagnosed Prevalent Cases of COPD Based on Severity of Airflow Limitation in Japan
7.7.5 Diagnosed Prevalent Cases of COPD Based on Symptoms and Exacerbation History in Japan

8 Patient Journey

9 Organizations contributing towards Chronic Obstructive Pulmonary Disease (COPD)

10 Marketed Therapies
10.1 Duaklir Pressair/Duaklir Genuair (Aclidinium Bromide and Formoterol Fumarate): AstraZeneca/Circassia Pharmaceuticals Inc.
10.1.1 Product Description
10.1.2 Regulatory Milestones
10.1.3 Other Developmental activities
10.1.4 Clinical Development
10.1.5 Clinical Trials Information
10.1.6 Safety and Efficacy
10.1.7 Product Profile
10.2 Advair Diskus/Adoair Diskus/Seretide Diskus (Fluticasone Propionate and Salmeterol Xinafoate): GlaxoSmithKline
10.2.1 Product Description
10.2.2 Regulatory Milestones
10.2.3 Other Developmental activities
10.2.4 Clinical Development
10.2.5 Clinical Trials Information
10.2.6 Safety and Efficacy
10.2.7 Product Profile
10.3 Symbicort (Budesonide and Formoterol Fumarate Dihydrate): AstraZeneca
10.3.1 Product Description
10.3.2 Regulatory Milestones
10.3.3 Other Developmental activities
10.3.4 Clinical Development
10.3.5 Clinical Trials Information
10.3.6 Safety and Efficacy
10.3.7 Product Profile
10.4 Anoro Ellipta (Umeclidinium Bromide and Vilanterol Trifenatate): GlaxoSmithKline/Theravance, Inc/Innoviva
10.4.1 Product Description
10.4.2 Regulatory Milestones
10.4.3 Other Developmental activities
10.4.4 Clinical Development
10.4.5 Clinical Trials Information
10.4.6 Safety and Efficacy
10.4.7 Product Profile
10.5 Incruse Ellipta/Encruse Ellipta (Umeclidinium Inhalation Powder): GlaxoSmithKline
10.5.1 Product Description
10.5.2 Regulatory Milestones
10.5.3 Other Developmental activities
10.5.4 Clinical Development
10.5.5 Clinical Trials Information
10.5.6 Safety and Efficacy
10.5.7 Product Profile
10.6 Trydonis (Beclometasone Dipropionate, Formoterol Fumarate Dihydrate, and Glycopyrronium): Chiesi Farmaceutici
10.6.1 Product Description
10.6.2 Regulatory Milestones
10.6.3 Other Developmental Activities
10.6.4 Clinical Development
10.6.5 Clinical Trials Information
10.6.6 Safety and Efficacy
10.6.7 Product Profile
10.7 Bevespi Aerosphere (Glycopyrronium/Formoterol Fumarate): AstraZeneca
10.7.1 Product Description
10.7.2 Regulatory Milestones
10.7.3 Other Developmental Activities
10.7.4 Clinical Development
10.7.5 Clinical Trials Information
10.7.6 Safety and Efficacy
10.7.7 Product Profile
10.8 Brovana (Arformoterol tartrate): Sunovion Pharmaceuticals
10.8.1 Product Description
10.8.2 Regulatory Milestones
10.8.3 Other Developmental Activities
10.8.4 Safety and Efficacy
10.8.5 Product Profile
10.9 Spiriva HandiHaler (Tiotropium Bromide Inhalation Powder): Boehringer Ingelheim Pharmaceuticals
10.9.1 Product Description
10.9.2 Regulatory Milestones
10.9.3 Other Developmental Activities
10.9.4 Safety and Efficacy
10.9.5 Product Profile
10.1 Eklira Genuair/Tudorza Pressair/Betrays Genuair (Aclidinium Bromide Inhalation Powder): AstraZeneca
10.10.1 Product Description
10.10.2 Regulatory Milestones
10.10.3 Other Developmental Activities
10.10.4 Clinical Development
10.10.5 Clinical Trials Information
10.10.6 Safety and Efficacy
10.10.7 Product Profile
10.11 Breztri Aerosphere/Trixeo Aerosphere (Budesonide/Glycopyrrolate/Formoterol Fumarate): AstraZeneca
10.11.1 Product Description
10.11.2 Regulatory Milestones
10.11.3 Other Developmental Activities
10.11.4 Clinical Development
10.11.5 Clinical Trials Information
10.11.6 Safety and Efficacy
10.11.7 Product Profile
10.12 Trelegy Ellipta (Fluticasone Furoate/Umeclidinium/ Vilanterol): GlaxoSmithKline
10.12.1 Product Description
10.12.2 Regulatory Milestones
10.12.3 Other Developmental activities
10.12.4 Clinical Development
10.12.5 Clinical Trials Information
10.12.6 Safety and Efficacy
10.12.7 Product Profile
10.13 Breo Ellipta/Relvar Ellipta (Fluticasone Furoate and Vilanterol): GlaxoSmithKline
10.13.1 Product Description
10.13.2 Regulatory Milestones
10.13.3 Other Developmental activities
10.13.4 Safety and Efficacy
10.13.5 Product Profile
11 Emerging Drugs
11.1 Key Cross Competition
11.2 Itepekimab (SAR440340/REGN3500/Anti-IL-33 mAb): Sanofi/Regeneron Pharmaceuticals
11.2.1 Product Description
11.2.2 Other Developmental Activities
11.2.3 Clinical Development
11.2.4 Clinical Trials Information
11.2.5 Product Profile
11.3 Dupixent (Dupilumab): Regeneron Pharmaceuticals/Sanofi
11.3.1 Drug Description
11.3.2 Other Developmental Activities
11.3.3 Clinical Development
11.3.4 Clinical Trials Information
11.3.5 Product Profile
11.3.6 Analysts? Views
11.4 Tyvaso (Inhaled treprostinil solution): United Therapeutics
11.4.1 Product Description
11.4.2 Other Developmental Activities
11.4.3 Clinical Development
11.4.4 Clinical Trials Information
11.4.5 Product Profile
11.5 Ensifentrine (RPL554): Verona Pharma PLC
11.5.1 Product Description
11.5.2 Other Developmental Activities
11.5.3 Clinical Development
11.5.4 Clinical Trials Information
11.5.5 Safety and Efficacy
11.5.6 Product Profile
11.5.7 Analysts? Views
11.6 Fasenra (Benralizumab): AstraZeneca
11.6.1 Drug Description
11.6.2 Other Developmental Activities
11.6.3 Clinical Development
11.6.4 Clinical Trials Information
11.6.5 Safety and Efficacy
11.6.6 Product Profile
11.6.7 Analysts’ Views
11.7 CHF6001 (Tanimilast): Chiesi Farmaceutici S.p.A.
11.7.1 Drug Description
11.7.2 Clinical Development
11.7.3 Clinical Trials Information
11.7.4 Safety and Efficacy
11.7.5 Product Profile
11.8 Nucala (Mepolizumab): GlaxoSmithKline
11.8.1 Drug Description
11.8.2 Other Developmental Activities
11.8.3 Clinical Development
11.8.4 Clinical Trials Information
11.8.5 Safety and Efficacy
11.8.6 Product Profile
11.8.7 Analysts’ Views
11.9 MV130 (Bactek): Inmunotek
11.9.1 Product Description
11.9.2 Clinical Development
11.9.3 Clinical Trials Information
11.9.4 Product Profile
11.10 MEDI3506: AstraZeneca
11.10.1 Product Description
11.10.2 Other Developmental Activities
11.10.3 Clinical Development
11.10.4 Clinical Trials Information
11.10.5 Product Profile
11.11 SelK2: Tetherex Pharmaceuticals Corporation
11.11.1 Product Description
11.11.2 Other Developmental Activities
11.11.3 Clinical Development
11.11.4 Clinical Trials Information
11.11.5 Product Profile
11.12 Epeleuton (DS102): Afimmune
11.12.1 Product Description
11.12.2 Other Developmental Activities
11.12.3 Clinical Development
11.12.4 Clinical Trials Information
11.12.5 Product Profile
11.13 NOV-14 (CSJ117): Novartis Pharmaceuticals
11.13.1 Product Description
11.13.2 Other Developmental Activities
11.13.3 Clinical Development
11.13.4 Clinical Trials Information
11.13.5 Product Profile
11.14 Zofin: Organicell Regenerative Medicine
11.14.1 Product Description
11.14.2 Other Developmental Activities
11.14.3 Clinical Development
11.14.4 Clinical Trials Information
11.14.5 Product Profile
11.15 NTHi Mcat investigational vaccine (GSK3277511A): GlaxoSmithKline
11.15.1 Product Description
11.15.2 Clinical Development
11.15.3 Clinical Trials Information
11.15.4 Safety and Efficacy
11.15.5 Product Profile
11.16 Icenticaftor (QBW251): Novartis Pharmaceuticals
11.16.1 Product Description
11.16.2 Clinical Development
11.16.3 Clinical Trials Information
11.16.4 Safety and Efficacy
11.16.5 Product Profile
11.17 Kalydeco (Ivacaftor/VX-770): Vertex Pharmaceuticals Incorporated
11.17.1 Product Description
11.17.2 Clinical Development
11.17.3 Clinical Trials Information
11.17.4 Safety and Efficacy
11.17.5 Product Profile
11.18 PUL-042 Inhalation Solution: Pulmotect Inc.
11.18.1 Drug Description
11.18.2 Other Developmental Activities
11.18.3 Clinical Development
11.18.4 Clinical Trials Information
11.18.5 Product Profile
11.19 Benlysta (Belimumab): GlaxoSmithKline
11.19.1 Drug Description
11.19.2 Other Developmental Activities
11.19.3 Clinical Development
11.19.4 Clinical Trials Information
11.19.5 Product Profile
11.20 Azithromycin: Genentech
11.20.1 Drug Description
11.20.2 Clinical Development
11.20.3 Clinical Trials Information
11.20.4 Product Profile
11.21 Tezepelumab: AstraZeneca/Amgen
11.21.1 Drug Description
11.21.2 Other Developmental Activities
11.21.3 Clinical Development
11.21.4 Clinical Trials Information
11.21.5 Product Profile
11.22 Acumapimod (BCT-197): Mereo BioPharma
11.22.1 Drug Description
11.22.2 Other Developmental Activities
11.22.3 Clinical Development
11.22.4 Clinical Trials Information
11.22.5 Safety and Efficacy
11.22.6 Product Profile
11.23 BIO-11006 Inhalation Solution: Biomarck Pharmaceuticals
11.23.1 Drug Description
11.23.2 Other Developmental Activities
11.23.3 Clinical Development
11.23.4 Clinical Trials Information
11.23.5 Safety and Efficacy
11.23.6 Product Profile

12 Potential of Emerging and Current therapies

13 Chronic Obstructive Pulmonary Disease (COPD): Seven Major Market Analysis
13.1 Key Findings
13.2 Market Size of Chronic Obstructive Pulmonary Disease in the 7MM
13.3 Market Size by Therapies of Chronic Obstructive Pulmonary Disease
13.3.1 Market Size of Chronic Obstructive Pulmonary Disease by Class
13.4 Key Market Forecast Assumptions
13.5 Attribute Analysis
13.6 Market Outlook
13.7 Market size of Chronic Obstructive Pulmonary Disease in the United States
13.7.1 Total Market size of Chronic Obstructive Pulmonary Disease
13.7.2 Market Size by Therapies of Chronic Obstructive Pulmonary Disease
13.7.2.1 Market Size of Chronic Obstructive Pulmonary Disease by Class
13.7.2.2 Market Size of Chronic Obstructive Pulmonary Disease by Therapies
13.8 Market size of Chronic Obstructive Pulmonary Disease in EU-5
13.8.1 Total Market size of Chronic Obstructive Pulmonary Disease in EU5
13.8.2 Market Size of Chronic Obstructive Pulmonary Disease by Class in EU5
13.8.2.1 Germany
13.8.2.2 France
13.8.2.3 Italy
13.8.2.4 Spain
13.8.2.5 United Kingdom
13.8.3 Market Size of Chronic Obstructive Pulmonary Disease by Therapies in EU5
13.8.3.1 Germany
13.8.3.2 France
13.8.3.3 Italy
13.8.3.4 Spain
13.8.3.5 United Kingdom
13.9 Market size of Chronic Obstructive Pulmonary Disease in Japan
13.9.1 Total Market size of Chronic Obstructive Pulmonary Disease
13.9.2 Market Size by Therapies of Chronic Obstructive Pulmonary Disease
13.9.2.1 Market Size of Chronic Obstructive Pulmonary Disease by Class
13.9.2.2 Market Size of Chronic Obstructive Pulmonary Disease by Therapies

14 KOL Views

15 Market Drivers

16 Market Barriers

17 SWOT Analysis

18 Unmet Needs

19 Reimbursement and Market Access
19.1 United States
19.2 Europe
19.3 Japan

20 Appendix
20.1 Bibliography
20.2 Report Methodology

21 DelveInsight Capabilities

22 Disclaimer

23 About DelveInsight



List of Figures

Figure 1 Etiology, Pathobiology, Pathology of COPD Leading to Airflow Limitation and Clinical Manifestations
Figure 2 Types of COPD – Emphysema and Chronic Bronchitis
Figure 3 Pathways of the Diagnosis of COPD
Figure 4 Spirometry Tracing in Normal Individual Versus Spirometry Tracing Typical of a Patient With Obstructive Disease
Figure 5 ABCD Assessment Tool
Figure 6 Diagnostic Algorithm of the Clinical Phenotypes
Figure 7 Flowchart for the Treatment of Stable Chronic Obstructive Pulmonary Disease (COPD)
Figure 8 Bronchodilator Therapy for Patients With Confirmed, Stable COPD
Figure 9 Algorithm for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
Figure 10 Follow-up Pharmacological Treatment
Figure 11 Total Diagnosed Prevalent Patient Population of Chronic Obstructive Pulmonary Disease in the 7MM, in Thousand (K) (2018–2030)
Figure 12 Diagnosed Prevalent Cases of COPD in the United States, in Thousand (K) (2018–2030)
Figure 13 Gender-specific Diagnosed Prevalent Cases of COPD in the United States, in Thousand (K) (2018–2030)
Figure 14 Age-specific Diagnosed Prevalent Cases of COPD in the United States, in Thousand (K) (2018–2030)
Figure 15 Diagnosed Prevalent Cases of COPD Based on Severity of Airflow Limitation in the United States, in Thousand (K) (2018–2030)
Figure 16 Diagnosed Prevalent Cases of COPD Based on Symptoms and Exacerbation History in the United States, in Thousand (K) (2018–2030)
Figure 17 Diagnosed Prevalent Cases of COPD in Europe, in Thousand (K) (2018–2030)
Figure 18 Gender-specific Diagnosed Prevalent Cases of COPD in Europe, in Thousand (K) (2018–2030)
Figure 19 Age-specific Diagnosed Prevalent Cases of COPD in Europe, in Thousand (K) (2018–2030)
Figure 20 Diagnosed Prevalent Cases of COPD Based on Severity of Airflow Limitation in Europe, in Thousand (K) (2018–2030)
Figure 21 Diagnosed Prevalent Cases of COPD Based on Symptoms and Exacerbation History in Europe, in Thousand (K) (2018–2030)
Figure 22 Diagnosed Prevalent Cases of COPD in Japan, in Thousand (K) (2018–2030)
Figure 23 Gender-specific Diagnosed Prevalent Cases of COPD in Japan, in Thousand (K) (2018–2030)
Figure 24 Age-specific Diagnosed Prevalent Cases of COPD in Japan, in Thousand (K) (2018–2030)
Figure 25 Diagnosed Prevalent Cases of COPD Based on Severity of Airflow Limitation in Japan, in Thousand (K) (2018–2030)
Figure 26 Diagnosed Prevalent Cases of COPD Based on Symptoms and Exacerbation History in Japan, in Thousand (K) (2018–2030)
Figure 27 Patient Journey
Figure 28 Market Size of Chronic Obstructive Pulmonary Disease in the 7MM in USD Million (2018–2030)
Figure 29 Market Size of Chronic Obstructive Pulmonary Disease by Class in the 7MM, in USD Million (2018–2030)
Figure 30 Market Size of Chronic Obstructive Pulmonary Disease in the United States, USD Millions (2018–2030)
Figure 31 Market Size of Chronic Obstructive Pulmonary Disease by Class in the United States, in USD Million (2018–2030)
Figure 32 Market Size of Chronic Obstructive Pulmonary Disease in EU5, USD Millions (2018–2030)
Figure 33 Market Size of Chronic Obstructive Pulmonary Disease by Class in EU5, in USD Million (2018–2030)
Figure 34 Market Size of Chronic Obstructive Pulmonary Disease in Japan, USD Millions (2018–2030)
Figure 35 Market Size of Chronic Obstructive Pulmonary Disease by Class in Japan, in USD Million (2018–2030)
Figure 36 Market Drivers
Figure 37 Market Barriers
Figure 38 SWOT Analysis
Figure 39 Unmet Needs

List of Tables

Table 1 Summary of COPD Market and Epidemiology (2018–2030)
Table 2 Key Events
Table 3 COPD Classification According to Symptom and Severity Risk
Table 4 Key Indicators for Considering a Diagnosis for COPD
Table 5 Classification of Airflow Limitation Severity in COPD (Based on Post-bronchodilator FEV1)
Table 6 Differential Diagnosis of COPD
Table 7 Pharmacological Characteristics of Approved Bronchodilators for COPD Treatment
Table 8 Pharmacological Treatment of COPD Based on Phenotypes and Disease Severity (GOLD stage I–IV)
Table 9 Antibiotic Dosing for Treatment of COPD Exacerbations
Table 10 Pharmacologic Options That are not Recommended for COPD
Table 11 Key points
Table 12 Vaccination For Stable COPD
Table 13 Total Diagnosed Prevalent Population of Chronic Obstructive Pulmonary Disease in the 7MM, in Thousand (K) (2018–2030)
Table 14 Diagnosed Prevalent Cases of COPD in the United States, in Thousand (K) (2018–2030)
Table 15 Gender-specific Diagnosed Prevalent Cases of COPD in the United States, in Thousand (K) (2018–2030)
Table 16 Age-specific Diagnosed Prevalent Cases of COPD in the United States, in Thousand (K) (2018–2030)
Table 17 Diagnosed Prevalent Cases of COPD Based on Severity of Airflow Limitation in the United States, in Thousand (K) (2018–2030)
Table 18 Diagnosed Prevalent Cases of COPD Based on Symptoms and Exacerbation History in the United States, in Thousand (K) (2018–2030)
Table 19 Diagnosed Prevalent Cases of COPD in Europe, in Thousand (K) (2018–2030)
Table 20 Gender-specific Diagnosed Prevalent Cases of COPD in Europe, in Thousand (K) (2018–2030)
Table 21 Age-specific Diagnosed Prevalent Cases of Chronic Obstructive Pulmonary Disease in Europe, in Thousand (K) (2018–2030)
Table 22 Diagnosed Prevalent Cases of COPD Based on Severity of Airflow Limitation in Europe, in Thousand (K) (2018–2030)
Table 23 COPD Classification Based on Severity of Airflow Limitation in Europe, in Thousand (K) (2018–2030)
Table 24 Diagnosed Prevalent Cases of COPD in Japan, in Thousand (K) (2018–2030)
Table 25 Gender-specific Diagnosed Prevalent Cases of COPD in Japan, in Thousand (K) (2018–2030)
Table 26 Age-specific Diagnosed Prevalent Cases of COPD in Japan, in Thousand (K) (2018–2030)
Table 27 Diagnosed Prevalent Cases of COPD Based on Severity of Airflow Limitation in Japan, in Thousand (K) (2018–2030)
Table 28 Diagnosed Prevalent Cases of COPD Based on Symptoms and Exacerbation History in Japan, in Thousand (K) (2018–2030)
Table 29 Organizations contributing toward COPD
Table 30 Comparison of Approved Drugs for COPD (1/4)
Table 31 Comparison of approved drugs for COPD (2/4)
Table 32 Comparison of approved drugs for COPD (3/4)
Table 33 Comparison of approved drugs for COPD (4/4)
Table 34 Duaklir Pressair/Duaklir Genuair, Clinical Trial Description, 2021
Table 35 Advair Diskus, Clinical Trial Description, 2021
Table 36 Symbicort, Clinical Trial Description, 2021
Table 37 Anoro Ellipta, Clinical Trial Description, 2021
Table 38 Incruse Ellipta, Clinical Trial Description, 2021
Table 39 Trydonis, Clinical Trial Description, 2021
Table 40 Glycopyrronium/formoterol fumarate, Clinical Trial Description, 2021
Table 41 Eklira Genuair/Tudorza Pressair/Bretaris Genuair, Clinical Trial Description, 2021
Table 42 Breztri Aerosphere/Trixeo Aerosphere, Clinical Trial Description, 2021
Table 43 Trelegy Ellipta, Clinical Trial Description, 2021
Table 44 Comparison of emerging drugs under development
Table 45 Itepekimab (SAR440340/REGN3500/Anti-IL-33 mAb), Clinical Trial Description, 2021
Table 46 Dupixent (Dupilumab/SAR231893), Clinical Trial Description, 2021
Table 47 Tyvaso (Inhaled Treprostinil Solution), Clinical Trial Description, 2021
Table 48 Ensifentrine, Clinical Trial Description, 2021
Table 49 Fasenra (Benralizumab), Clinical Trial Description, 2021
Table 50 CHF6001 (Tanimilast), Clinical Trial Description, 2021
Table 51 Nucala (Mepolizumab), Clinical Trial Description, 2021
Table 52 MV130 (Bactek), Clinical Trial Description, 2021
Table 53 MEDI3506, Clinical Trial Description, 2021
Table 54 SelK2, Clinical Trial Description, 2021
Table 55 Epeleuton (DS102), Clinical Trial Description, 2021
Table 56 NOV-14 (CSJ117), Clinical Trial Description, 2021
Table 57 Zofin, Clinical Trial Description, 2021
Table 58 NTHi Mcat investigational vaccine (GSK3277511A), Clinical Trial Description, 2021
Table 59 Icenticaftor (QBW251), Clinical Trial Description, 2021
Table 60 Kalydeco (Ivacaftor/VX-770), Clinical Trial Description, 2021
Table 61 PUL-042 Inhalation Solution, Clinical Trial Description, 2021
Table 62 Benlysta (Belimumab), Clinical Trial Description, 2021
Table 63 Azithromycin, Clinical Trial Description, 2021
Table 64 Tezepelumab, Clinical Trial Description, 2021
Table 65 Acumapimod, Clinical Trial Description, 2021
Table 66 BIO-11006, Clinical Trial Description, 2021
Table 67 Market Size of Chronic Obstructive Pulmonary Disease in the 7MM in USD Million (2018–2030)
Table 68 Market Size of Chronic Obstructive Pulmonary Disease by Class in the 7MM, in USD Million (2018–2030)
Table 69 Key Market Forecast Assumptions for Itepekimab
Table 70 Key Market Forecast Assumptions for Ensifentrine
Table 71 Key Market Forecast Assumptions for Dupilumab
Table 72 Key Market Forecast Assumptions for Benralizumab
Table 73 Key Market Forecast Assumptions for Mepolizumab
Table 74 Key Market Forecast Assumptions for CHF6001/Tanimilast
Table 75 Key Market Forecast Assumptions for Acumapimod (BCT-197)
Table 76 United States Market Size of Chronic Obstructive Pulmonary Disease in USD Million (2018–2030)
Table 77 Market Size of Chronic Obstructive Pulmonary Disease by Class in the United States, in USD Million (2018–2030)
Table 78 Market Size of Chronic Obstructive Pulmonary Disease by Therapies in the United States, in USD Million (2018–2030)
Table 79 EU-5 Market Size of Chronic Obstructive Pulmonary Disease in USD Million (2018–2030)
Table 80 Market Size of Chronic Obstructive Pulmonary Disease by Class in EU5, in USD Million (2018–2030)
Table 81 Market Size of Chronic Obstructive Pulmonary Disease by Class in Germany, in USD Million (2018–2030)
Table 82 Market Size of Chronic Obstructive Pulmonary Disease by Class in France, in USD Million (2018–2030)
Table 83 Market Size of Chronic Obstructive Pulmonary Disease by Class in Italy, in USD Million (2018–2030)
Table 84 Market Size of Chronic Obstructive Pulmonary Disease by Class in Spain, in USD Million (2018–2030)
Table 85 Market Size of Chronic Obstructive Pulmonary Disease by Class in the UK, in USD Million (2018–2030)
Table 86 Market Size of Chronic Obstructive Pulmonary Disease by Therapies in EU5, in USD Million (2018–2030)
Table 87 Market Size of Chronic Obstructive Pulmonary Disease by Therapies in Germany, in USD Million (2018–2030)
Table 88 Market Size of Chronic Obstructive Pulmonary Disease by Therapies in France, in USD Million (2018–2030)
Table 89 Market Size of Chronic Obstructive Pulmonary Disease by Therapies in Italy, in USD Million (2018–2030)
Table 90 Market Size of Chronic Obstructive Pulmonary Disease by Therapies in Spain, in USD Million (2018–2030)
Table 91 Market Size of Chronic Obstructive Pulmonary Disease by Therapies in the UK, in USD Million (2018–2030)
Table 92 Market Size of Chronic Obstructive Pulmonary Disease in Japan, in USD Million (2018–2030)
Table 93 Market Size of Chronic Obstructive Pulmonary Disease by Class in Japan, in USD Million (2018–2030)
Table 94 Market Size of Chronic Obstructive Pulmonary Disease by Therapies in Japan, in USD Million (2018–2030)